Amphastar Pharmaceuticals Stock Forecast, Price & News

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

Is Amphastar Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Amphastar Pharmaceuticals?

Wall Street analysts have given Amphastar Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amphastar Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Amphastar Pharmaceuticals.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings results on Sunday, August, 8th. The company reported $0.21 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.21. The company had revenue of $101.66 million for the quarter, compared to the consensus estimate of $101.38 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 8.01% and a net margin of 2.72%.
View Amphastar Pharmaceuticals' earnings history.

How has Amphastar Pharmaceuticals' stock been impacted by Coronavirus?

Amphastar Pharmaceuticals' stock was trading at $15.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMPH stock has increased by 25.4% and is now trading at $19.19.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AMPH?

2 analysts have issued twelve-month price targets for Amphastar Pharmaceuticals' shares. Their forecasts range from $20.00 to $23.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 12.0% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:

• Zi Ping Luo, Chairman, COO & Chief Scientist
• Yong Feng Zhang, President, Chief Executive & Scientific Officer
• William J. Peters, Chief Financial Officer, Treasurer & SVP-Finance (LinkedIn Profile)
• Rong Zhou, Executive Vice President-Production Center (LinkedIn Profile)
• Jacob Liawatidewi, Secretary & EVP-Corporate Administration Centre (LinkedIn Profile)

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amphastar Pharmaceuticals' key competitors?

Some companies that are related to Amphastar Pharmaceuticals include Arena Pharmaceuticals (ARNA), Aurinia Pharmaceuticals (AUPH), Cryoport (CYRX), Reata Pharmaceuticals (RETA), Zentalis Pharmaceuticals (ZNTL), Intra-Cellular Therapies (ITCI), Galapagos (GLPG), Lyell Immunopharma (LYEL), Insmed (INSM), Hypera (HYPMY), Cytokinetics (CYTK), Nektar Therapeutics (NKTR), ACADIA Pharmaceuticals (ACAD), Prestige Consumer Healthcare (PBH) and Agios Pharmaceuticals (AGIO).
View all of AMPH's competitors.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (0.53%), Assenagon Asset Management S.A. (0.37%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.06%), Louisiana State Employees Retirement System (0.04%) and Strs Ohio (0.01%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals.

Which institutional investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Nisa Investment Advisors LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, and Strs Ohio.
View insider buying and selling activity for Amphastar Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $19.19.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals has a market capitalization of $921.73 million and generates $349.85 million in revenue each year. The company earns $1.40 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,980 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

Where are Amphastar Pharmaceuticals' headquarters?

Amphastar Pharmaceuticals is headquartered at 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at (909) 980-9484 or via email at [email protected].